These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 10280126)

  • 21. Minimizing antitrust risks of Blue Cross and Blue Shield plans.
    Steele CJ
    J Contemp Health Law Policy; 1988; 4():227-72. PubMed ID: 10288422
    [No Abstract]   [Full Text] [Related]  

  • 22. Prognosis: prison? Health care providers, as they set up new business arrangements in this era of rising medical costs, risk running afoul of federal antitrust and antifraud laws.
    Kosterlitz J
    Natl J (Wash); 1989 Jun; 21(24):1576-7, 1582-4. PubMed ID: 10293560
    [No Abstract]   [Full Text] [Related]  

  • 23. Are PPOs a competitive force or antitrust risk?
    Enders RJ
    Healthc Financ Manage; 1986 May; 40(5):52-60. PubMed ID: 10276171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The FTC and provider-controlled PPO price negotiations.
    Miles JJ
    Health Law Vigil; 1988 Jan; 11(3):6-10. PubMed ID: 10285716
    [No Abstract]   [Full Text] [Related]  

  • 25. Antitrust and third party insurers.
    Heitler G
    Am J Law Med; 1982; 8(3):251-70. PubMed ID: 7168451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Joint ventures: don't let the law take you by surprise.
    Stevens C
    Med Econ; 1987 Mar; 64(7):52-7, 61. PubMed ID: 10281442
    [No Abstract]   [Full Text] [Related]  

  • 27. Special report on antitrust. Part Two: Hidden antitrust risks in joint ventures.
    Enders RJ
    Health Care Law Newsl; 1988 Mar; 3(3):12-5. PubMed ID: 10286207
    [No Abstract]   [Full Text] [Related]  

  • 28. Hospital joint ventures: charting a safe course through a sea of antitrust regulations.
    Joseph JM
    Am J Law Med; 1988; 13(4):621-42. PubMed ID: 3064588
    [No Abstract]   [Full Text] [Related]  

  • 29. Monopolies, Maricopa, and marketing: a case study.
    Perkins J; Mercer A; McClary C
    Hosp Health Serv Adm; 1986; 31(4):34-44. PubMed ID: 10277339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacy participation in PPOs: an antitrust review.
    Health Matrix; 1984-1985 Winter; 2(4):35-7. PubMed ID: 10272758
    [No Abstract]   [Full Text] [Related]  

  • 31. FTC letter further confuses PPO price-fixing issue.
    Miles JJ
    Health Law Vigil; 1986 May; 9(9):5-7. PubMed ID: 10276714
    [No Abstract]   [Full Text] [Related]  

  • 32. Can provider antitrust suits against payers be successful?
    Enders RJ
    Healthc Financ Manage; 1986 Jun; 40(6):72-80. PubMed ID: 10276682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proposed FTC consent order first to prohibit PPO price-fixing and concerted negotiations.
    Miles JJ
    Health Law Vigil; 1988 Jan; 11(2):9-10, 14. PubMed ID: 10285312
    [No Abstract]   [Full Text] [Related]  

  • 34. Antitrust and health care: provider controlled health plans and the Maricopa decision.
    Weller CD
    Am J Law Med; 1982; 8(3):223-49. PubMed ID: 6897759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liability and insurance issues.
    Bergin MA
    Top Health Care Financ; 1986; 13(1):57-68. PubMed ID: 3764896
    [No Abstract]   [Full Text] [Related]  

  • 36. Physicians and PPOs: antitrust lessons from Maricopa.
    Finke RF; Gary M
    Hosp Med Staff; 1983 Jul; 12(7):10-5. PubMed ID: 10278175
    [No Abstract]   [Full Text] [Related]  

  • 37. Federal antitrust agencies send mixed signals to PPOs.
    Enders RJ
    Health Care Law Newsl; 1986 Jul; 1(1):12-4. PubMed ID: 10277502
    [No Abstract]   [Full Text] [Related]  

  • 38. Minimizing antitrust and corporate liability risks.
    Weissburg C
    Health Prog; 1987 Apr; 68(3):68-73, 90. PubMed ID: 10282282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician organizations as payment negotiators: antitrust issues.
    Barnes CE; Hastings DA
    Physician Exec; 1987; 13(2):26-7. PubMed ID: 10312042
    [No Abstract]   [Full Text] [Related]  

  • 40. Staying within those antitrust "safety zones".
    Walker LM
    Med Econ; 1994 May; 71(10):52, 55, 59. PubMed ID: 10133949
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.